{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:02:53Z","timestamp":1790650973869,"version":"4.1.0"},"reference-count":23,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:00:00Z","timestamp":1676073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathophysiology"],"abstract":"<jats:p>The prevalence of opioid use among pregnant people has been increasing over the past few decades, with a parallel increase in the rate of neonatal abstinence syndrome. Opioid agonist treatment (OAT) including methadone and buprenorphine is the recommended management method for opioid use disorders during pregnancy. Methadone has been extensively studied during pregnancy; however, buprenorphine was introduced in the early 2000s with limited data on the use of different preparations during pregnancy. Buprenorphine-naloxone has been incorporated into routine practice; however, only a few studies have investigated the use of this medication during pregnancy. To determine the safety and efficacy of this medication, we conducted a systematic review of maternal and neonatal outcomes among buprenorphine-naloxone-exposed pregnancies. The primary outcomes of interest were birth parameters, congenital anomalies, and severity of neonatal abstinence syndrome. Secondary maternal outcomes included the OAT dose and substance use at delivery. Seven studies met the inclusion criteria. Buprenorphine-naloxone doses ranged between 8 and 20 mg, and there was an associated reduction of opioid use during pregnancy. There were no significant differences in gestational age at delivery, birth parameters, or prevalence of congenital anomalies between buprenorphine-naloxone-exposed neonates and those exposed to methadone, buprenorphine monotherapy, illicit opioids, or no opioids. In studies comparing buprenorphine-naloxone to methadone, there were reduced rates of neonatal abstinence syndrome requiring pharmacotherapy. These studies demonstrate that buprenorphine-naloxone is a safe and effective opioid agonist treatment for pregnant people with OUD. Further large-scale, prospective data collection is required to confirm these findings. Patients and clinicians may be reassured about the use of buprenorphine-naloxone during pregnancy.<\/jats:p>","DOI":"10.3390\/pathophysiology30010004","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T06:09:21Z","timestamp":1676268561000},"page":"27-36","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-9829","authenticated-orcid":false,"given":"Alice","family":"Ordean","sequence":"first","affiliation":[{"name":"Department of Family Medicine, St. Joseph\u2019s Health Centre, Unity Health Toronto, Toronto, ON M6R 1B5, Canada"},{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meara","family":"Tubman-Broeren","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jogc.2017.04.028","article-title":"SOGC clinical practice guideline no. 349\u2014Substance use in pregnancy","volume":"39","author":"Ordean","year":"2017","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_2","unstructured":"British Columbia Centre on Substance Use, B.C. Ministry of Health, B.C. Ministry of Mental Health and Addictions, & Perinatal Services BC (2022, March 29). A Guideline for the Clinical Management of Opioid Use Disorder\u2014Pregnancy Supplement. Available online: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2018\/06\/OUD-Pregnancy.pdf."},{"key":"ref_3","unstructured":"Substance Abuse and Mental Health Services Administration (2022, March 29). 2020 National Survey on Drug Use and Health: Detailed Tables. Table 6.20B\u2014Types of Illicit Drug, Tobacco Product, and Alcohol Use in Past Month: Among Females Aged 15 to 44; by Pregnancy Status, Percentages, 2019 and 2020, Available online: https:\/\/www.samhsa.gov\/data\/report\/2020-nsduh-detailed-tables."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010\u20132017","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1360-0443.2012.04035.x","article-title":"Buprenorphine treatment of opioid-dependent pregnant women: A comprehensive review","volume":"107","author":"Jones","year":"2012","journal-title":"Addiction"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"American College of Obstetricians and Gynecologists (2017). Opioid use and opioid use disorder in pregnancy\u2014Committee opinion no. 711. Obstet. Gynecol., 130, e81\u2013e94.","DOI":"10.1097\/AOG.0000000000002235"},{"key":"ref_8","unstructured":"British Columbia Centre on Substance Use and B.C. Ministry of Health (2022, March 29). 286 A Guideline for the Clinical Management of Opioid Use Disorder. Available online: https:\/\/bccsu.ca\/wp-content\/uploads\/2018\/06\/OUD-Pregnancy.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"J. Addict. Med."},{"key":"ref_10","unstructured":"Substance Abuse and Mental Health Services Administration (2022, March 29). Clinical Guidance for Treating Pregnant and Parenting Women with Opioid Use Disorder and their Infants. HHS Publication No. (SMA) 18-5054, Available online: https:\/\/store.samhsa.gov\/product\/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants\/SMA18-5054."},{"key":"ref_11","unstructured":"World Health Organization (2022, March 29). Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241548731."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1521-0391.2012.12005.x","article-title":"Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data","volume":"22","author":"Debelak","year":"2013","journal-title":"Am. J. Addict."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ajad.12687","article-title":"Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure","volume":"27","author":"Nguyen","year":"2018","journal-title":"Am. J. Addict."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/ADM.0000000000000562","article-title":"Buprenorphine and naloxone versus buprenorphine for opioid use disorder in pregnancy: A cohort study","volume":"14","author":"Mullins","year":"2020","journal-title":"J. Addict. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2050312114530282","DOI":"10.1177\/2050312114530282","article-title":"Neonatal outcomes following in utero exposure to buprenorphine\/naloxone or methadone","volume":"2","author":"Gawronski","year":"2014","journal-title":"SAGE Open Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/AOG.0000000000000640","article-title":"Buprenorphine and naloxone compared with methadone treatment in pregnancy","volume":"125","author":"Wiegand","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_17","first-page":"e194","article-title":"Buprenorphine-naloxone use in pregnancy for treatment of opioid dependence: Retrospective cohort study of 30 patients","volume":"62","author":"Dooley","year":"2016","journal-title":"Can. Fam. Physician"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e011774","DOI":"10.1136\/bmjopen-2016-011774","article-title":"Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population","volume":"6","author":"Jumah","year":"2016","journal-title":"BMJ Open"},{"key":"ref_19","unstructured":"Public Health Agency of Canada (2022, March 29). Congenital Anomalies in Canada 2013: A Perinatal Health Surveillance Report. Ottawa. Available online: https:\/\/publications.gc.ca\/site\/eng\/443924\/publication.html."},{"key":"ref_20","unstructured":"Data & Statistics on Birth Defects (2022, March 29). Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/ncbddd\/birthdefects\/data.html."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamapediatrics.2017.5195","article-title":"Association of rooming-in with outcomes for neonatal abstinence syndrome: A systematic review and meta-analysis","volume":"172","author":"MacMillan","year":"2018","journal-title":"JAMA Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1521-0391.2010.00086.x","article-title":"Buprenorphine-based regimens and methadone for the medical management of opioid dependence: Selecting the appropriate drug for treatment","volume":"19","author":"Maremmani","year":"2010","journal-title":"Am. J. Addict."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100179","DOI":"10.1016\/j.ajogmf.2020.100179","article-title":"Buprenorphine-naloxone use in pregnancy: A systematic review and metaanalysis","volume":"2","author":"Link","year":"2020","journal-title":"Am. J. Obstet. Gynecol. MFM"}],"container-title":["Pathophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1873-149X\/30\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:32:03Z","timestamp":1760121123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1873-149X\/30\/1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["pathophysiology30010004"],"URL":"https:\/\/doi.org\/10.3390\/pathophysiology30010004","relation":{},"ISSN":["1873-149X"],"issn-type":[{"value":"1873-149X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,11]]}}}